NEWARK, Calif. – December 10, 2024 – InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics for cardiac arrythmias, has announced that Myles Greenberg, MD, MBA will serve as its new president and CEO. Dr. Greenberg joins the company as it advances clinical development...
September 30, 2024 SAN FRANCISCO--(BUSINESS WIRE)--InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company announces results from the RESTORE-1 Phase 3 trial and plans for continued development. • Analysis of the results of the RESTORE-1 Phase 3 trial following its premature termination demonstrated statistically significant cardioversion of...
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial Fibrillation Topline Results from the Ongoing Pivotal Phase 3 RESTORE-1 Trial of InRhythm Expected in Early 2024 SAN FRANCISCO, Nov. 07, 2022 (GLOBE...
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as President and CEO; Will Serve as Consultant to Ensure Smooth Leadership Transition SAN FRANCISCO, CA – October 4,...
Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pick” in Circulation: Arrhythmia and Electrophysiology SAN FRANCISCO, CA – July 26, 2022 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company...
Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 San Francisco, CA – June 23, 2021 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held...
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens...
Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular...
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Provides Roadmap for Start of Pivotal Phase 3 in Medically Supervised Setting in 2021 San Francisco, CA...
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association Scientific Sessions 2020; Pivotal Phase 3 Study Planned for Initiation in H1 2021 SAN FRANCISCO, Oct. 21,...